sentence1 stringlengths 1.08k 96.5k | sentence2 stringlengths 51 966 | labels stringclasses 3
values | metadata stringlengths 123 2.56k |
|---|---|---|---|
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.2 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Incidence of minor hypoglycaemia | 1 | {"evidence_spans": [{"end": 26184, "start": 25524, "text": "oglycaemia occurred in < 10% of subjects for any treatment. The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (... |
TITLE: Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
ABSTRACT.BACKGROUND:
Endometriosis is associated with an inflammatory response. Hence infliximab, an anti-TNF-α monoclonal antibody, might relieve pain.
ABSTRACT.METHODS:
A randomized placebo-controlled t... | Intervention: Infliximab
Comparator: Placebo
Outcome: Dysmenorrhea scores | 0 | {"evidence_spans": [{"end": 1105, "start": 987, "text": "ESULTS:\r\nPain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P "}], "id": "191", "pmcid": "2517154", "prompt_id": "191", "split_group_id": "2517154", "votes": {"0": 1}} |
TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
ABSTRACT.AIM:
To compare the effects of combining liraglutide (0.6,... | Intervention: Liraglutide (1.8 mg) plus glimepiride
Comparator: Rosiglitazone plus glimepiride
Outcome: Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% | 1 | {"evidence_spans": [{"end": 16353, "start": 16120, "text": "d with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001"}, {"end": 16355, "start":... |
TITLE: Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
ABSTRACT.BACKGROUND:
Peripheral intravenous device (IVD) complications were traditionally thought to be reduced by limiting dwell time. Current... | Intervention: staff inclination replacement
Comparator: routine replacement
Outcome: IVD dwell times | 1 | {"evidence_spans": [{"end": 24633, "start": 24391, "text": "of 113 hours (quartiles 72 and 172 hours) (P = 0.21). For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell tim"}, {"end": 24799,... |
TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post-stroke
ABSTRACT.BACKGROUND:
While manually-assisted body-weight supported treadmill training (BWSTT) has revealed improved locomotor function in persons with post-stroke hemiparesis, outcomes are inconsistent and i... | Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)
Comparator: Body-weight supported treadmill training combined with Lokomat (Pre-test)
Outcome: Berg Balance Scale score | 1 | {"evidence_spans": [{"end": 24120, "start": 23992, "text": "ovements in 5 of 8 participants. Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect si"}], "id": "163", "pmcid": "2708184", "prompt_id": "163", "split_group_id": "2708184", "votes": {"1": 1}} |
"TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produ(...TRUNCATED) | "Intervention: Liraglutide (all doses) plus glimepiride\nComparator: Rosiglitazone plus glimepiride\(...TRUNCATED) | 0 | "{\"evidence_spans\": [{\"end\": 21012, \"start\": 20943, \"text\": \"mg (P = 0.01) and not liraglut(...TRUNCATED) |
"TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produ(...TRUNCATED) | "Intervention: Liraglutide (0.6 mg) plus glimepiride\nComparator: Placebo plus glimepiride\nOutcome:(...TRUNCATED) | -1 | "{\"evidence_spans\": [{\"end\": 14314, \"start\": 13955, \"text\": \"or rosiglitazone (\\u22120.4%)(...TRUNCATED) |
"TITLE: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an (...TRUNCATED) | "Intervention: Dihydroartemisinin-piperaquine\nComparator: Chloroquine\nOutcome: Parasite clearance (...TRUNCATED) | 0 | "{\"evidence_spans\": [{\"end\": 22940, \"start\": 22725, \"text\": \"k of clearance in chloroquine (...TRUNCATED) |
"TITLE: Pilot study of Lokomat versus manual-assisted treadmill training for locomotor recovery post(...TRUNCATED) | "Intervention: Body-weight supported treadmill training combined with Lokomat (Post-test)\nComparato(...TRUNCATED) | 1 | "{\"evidence_spans\": [{\"end\": 23991, \"start\": 23824, \"text\": \" group participants (Figure 2B(...TRUNCATED) |
"TITLE: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produ(...TRUNCATED) | "Intervention: Liraglutide (1.8 mg) plus glimepiride \nComparator: Placebo plus glimepiride \nOutcom(...TRUNCATED) | 0 | "{\"evidence_spans\": [{\"end\": 22230, \"start\": 22039, \"text\": \"ied forward. \\r\\n\\r\\nBODY.(...TRUNCATED) |
End of preview. Expand in Data Studio
evidence-inference
Evidence Inference v2: full article + intervention/comparator/outcome → effect direction.
Join annotations by PromptID AND PMCID, never by article alone. Use verified labels, exclude tied votes and upstream known-bad prompts. Evidence spans in metadata refer only to the same prompt and winning label. Full article text stays in the input so isolated snippets need not identify treatment arms. Native article train/validation/test splits are preserved. The upstream code and annotations have MIT terms; article-text rights vary and are not relabeled MIT. Mirror text/data licensing remains unspecified.
Original data: original distribution. Repackaged as parquet for tasksource by scripts/repackage_dataset/specialized_text.py.
Conversion provenance: source revisions, hashes, configuration and exclusions.
- Downloads last month
- 90